Episode 6: Management of Dyskalemias - podcast episode cover

Episode 6: Management of Dyskalemias

Sep 30, 202120 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Join KDIGO Conversations in Nephrology host, Dr. Roberto Pecoits-Filho, in conversation with Dr. Chuck Herzog as they explore the challenges that occur when managing dyskalemia. They address the consequences of hyperkalemia and hypokalemia. They also discuss how both hospitalized patients and outpatients are affected by hyperkalemia. Dr. Roberto Pecoits-Filho is Senior Research Scientist at Arbor Research and Professor of Medicine at the Pontifical Catholic University of Paraná. Dr. Chuck Herzog is Professor of Medicine at the University of Minnesota, and a cardiologist at Hennepin County Medical Center. This episode was supported by CSL Vifor.

Transcript

Welcome to que digo conversations in Nephrology this episode is titled management of disc elimi has for disclosure information. Please go to que digo dot org, slash podcasts. Here's your host dr. Roberto Papua filho. Hello and welcome to the KT book conversations and in frolla G I am dr. Gilberto pakhlava video on a frolla gist and Senior research

scientist at Arbor research. Liability for health, and a professor of medicine at the pontifical Catholic University of America, joining me to talk about the management of this Columbia is dr. Chuck, Herzog, professor of medicine at the University of Minnesota in a cardiologist, at the Hennepin Health Care, Chuck. Welcome to the program. Thanks very much Roberto. I'm very delighted to be here with you virtually. So check, let's Dive Right In. Let me ask you a basic. Good question.

What is the definition you use for this Colima? So it's been arbitrary and it's a partially based on population sampling. But acute hyperkalemia is defined and by the que digo group to be greater than 5.0, millimoles per liter, or above the reference range of the laboratory. If there is a reference range available which to me is not terribly helpful as a standalone threshold. And I'd like to just review the que digo classification scheme related to hyper Caitlin which I

think is a bit better. Hypokalemia is attractive, less attention is arbitrarily defined as less than 3.5 million moles per liter in the que digo, Miami consensus conference, which you and I both participated in the group came up with a classification scheme that both reflects plasma levels and the presence or absence of electrocardiographic changes. So mild hypokalemia was defined to be 5 to 5 .9, but at the same levels changed with ECG changes suggested.

Active of hyperkalemia defined to be moderate and consistent with this. A six to six point four was defined to be moderate without tcga changes and severe in the presence of changes, attributed to a hyperkalemia. And any patient with a value of 6, point 5 or higher acutely, to be considered to be a severe acute hyperkalemia. You are an experienced and seasoned clinician and see patients with hypo and hyperkalemia all the time. Right? Check.

And I wonder what is the thing? That just see as a biggest challenge that, in clinical, practice in the management of this, this Colinas. But do I think the biggest challenge is being able to Monitor and respond, appropriately in real time both to hyper and hypokalemia once available management algorithms, which are embedded in

electronic. Medical records can be helpful and they should be evaluated by East Institution for the safety and efficacy for the platform, being used on your own Campus, of course, many countries do not have Have electronic medical records, but you can do the same thing without an EMR. Using, you know, paper orders or even verbal orders. It's just takes a little longer to implement the carry them out, but the same algorithmic approach for treatment.

Can be applied across the board, no matter where you are. It's just a question of what the platform is, and what is the most important consequence of this episodes of hypo and hyperkalemia? That you see will ignore the noncardiac ones. The most important ones are arrhythmia both hyper and hypokalemia Don't lead to lethal arithmetic events such as torsade de Pointes degenerating into ventricular fibrillation, hypokalemia patients and also

asystole in severe. Hypokalemia people with severe hypokalemia besides having asystole can also develop a ventricular fibrillation. My personal experience, I would say in the setting of hypokalemia particularly in the Intensive Care Unit or an acute illness, I think that it also contributes to other rhythmic. Events, which are magnified by the comorbid conditions of whatever going on with the patient. Particularly one of those arrhythmias is atrial fibrillation.

So sometimes we see patients who come in with acute illness. Now, the question comes up is is the arrhythmia related to this case, atrial fibrillation is related to the low potassium levels, or is it just a coincidence? So in this type of setting, The normal range with self defined as 3.5 or higher 3.5. And actually might be too low because been electric physiologic standpoint, the

ideals serum potassium. I actually might be closer to four point five to 50 but this can be very hard to implement safely because if you think about clinical setting, there has to be a margin of safety on the upper end to acute hyperkalemia practice, we sort of aim for a sweet spot and our own EMR driven algorithms, the Spot is probably in the range of four point zero two four point three totally arbitrary. But that seems to be a reasonable place to be because

it gives safety on the high end. I think it is associated with better results than just shooting for 3.5. My own experience, is that not unusual to replace people's potassium levels? It come in with acute atrial fibrillation in the setting of acute illness. You correct the potassium and then they go into sinus rhythm.

Now, whether that's causal or coincidental, it's very hard to determine that, but I have to say this Just an observation that if I had a choice on where potassium levels going to be in a hospitalized patient, it's probably going to be a naming a goal of somewhere in the 4.0 to 4.2 or 4.3 range arbitrary but pretty much experience based. Well, thanks so much chuck. I really think that those tips are pretty useful in the daily management of this patients. We see all the time, Chuck.

You mentioned that being able to Monitor and respond quickly to disclaimers in real time is a special challenge. Challenge for us clinicians. It sounds like you had something minor. Yes, I think you can divide it

into two parts. First is appropriate treatment, which is probably actually the easier one because there are good treatment algorithms for acute hyperkalemia, and I would just refer the audience back to the que digo controversies conference document, which has a very nice flow diagram, which summarizes evidence-based therapy is. So, hypokalemia is actually attracted lesson.

Engine in the literature. And in my own institution, we have an EMR based treatment algorithm which actually predates, the electronic medical record and we started with old-fashioned paper charts. This was a literally, a five-year project. I spent time working with one of our Cardiology inpatient, pharmacist and the algorithm takes into account, both the dose of potassium and the timing and frequency of monitoring related to real time, serum

potassium. A sium, egfr concomitant medications, affecting potassium, levels, and type of IV access or ability to receive oral potassium replacement. I've also encourage clinicians dealing with patients, who are thickly those treating patients with acute, be compensated, heart failure, where there's a fairly large, diuresis and a concomitant Kelly erases to use the urine output and spot. You're in potassium as a Of anticipating ongoing, potassium

replacement requirements. So to spot Buren potassium's, 12 hours apart, take the average. And multiply times the 24 hour urine output. You have sort of a general reasonable idea of what what the patient lost in that 24 hour to period of time. And what they might perhaps

would need in the next 24 hours. I do encourage clinicians to think about this process because I think it's inherently safer to be doing this in a algorithmic approach rather than to just Just to do ad. Hoc, you know, or potassium orders were somebody has a low potassium and they get a, they just sort of the middle and I get a call and it's okay. We'll just do the potassium x amount of potassium, and that's not likely to be as safe or accurate in that proper

procedure. So, each Hospital needs to have its own approach, and hopefully it's been tested to, to make sure it works in the individual institution. Yeah, and I fully agree with you, that the hypokalemia has not received enough attention, despite being a big big. Clinical problem. Now, remember this generated interesting discussions in the Miami meeting during our que digo controversies meeting on the management of hypokalemia.

And by the way, just reminding our audience that the report of the meeting is available in a publication that came out on King International and is free for access at the KD website. So, for those turning in just now, you're listening to the que digo conversations in frolla G Today's episode is on management of disclaimers. I am Hobart to pick waffle you and here with me, is dr. Chuck Herzog.

Okay, so let's shift to the other side of the spectrum of the scalia's and talk about hyperkalemia. What are your thoughts about big challenges in patients presenting with high potassium levels? Thank you. That's a good question. It's also a little more complicated. I think the most challenging issue is what I would refer to as the unexpected trajectory of acute hyperkalemia. Hospitalized patients, James wedmore. And I recently published a paper in the American Heart journal on

hypokalemia and hyperkalemia. In hospitalized patients at our own institution, using our electronic medical record.

The paper covered five years of hospitalizations 2012 through 2016 and we actually had at our disposal nearly 100,000 admissions where it's a serum potassium was done and then to be make this Methods, a little more rigorous we randomly picked one unique hospitalization, at a patient level, so that we were not affected by Survivor bias by having people with multiple potassium levels over different hospitalizations.

So we had a sample of 47,000 unique hospitalizations over five years, where a potassium value was available randomly selected from all hospitalizations. And in this study 1.3 percent of those 47 thousand patients and a potassium value of at least 60. Fire and a little over 4% had a potassium value of a below 3.5. So it's not something that's frequent but it's enough to be of concern.

One of the things about the analysis, which struck me as being quite important, was that in some of the patients with hyperkalemia, there was an unusually rapid trajectory and I would use the analogy of commercial Aviation to think about this where, if a pilot does not realize how fast a plane might be descending. Being and responds to late with dire consequences, like the plane crashes because they actually didn't know how fast they were following.

The same thing sort of strikes me as being similar with the acute hyperkalemia example, where it's the clinicians, don't realize how fast the potassium value is rising. They will be caught unawares, and with very potentially dire consequences to the patient, because they didn't have enough time to respond to the rapidly changing value. And to start treatment, I would refer the audience.

To the paper to take a look because it's fairly dense, but I think it's an interesting study because it's very difficult to construct these type of temporally driven studies without a good EMR. So let's take a look. If you have a chance. So the take-home message is potassium levels can rise faster than you might think is a cute hypokalemia really only a problem for hospitalized patients. Chuck? Well, no, not really, of course not but you know, it It is

presented question. If we actually don't monitor outpatients closely, then acute or chronic hyperkalemia can cause out-of-hospital sudden cardiac death and how would we know that was the reason if we weren't actually monitoring them. So it's it may be more of a monitoring issue. There's also a widely held perception that I think is really unique to the Nephrology world that chronic hyperkalemia is.

Well, tolerated, including the belief and I say it's a belief, it's not really based on any Ones that are hyperkalemic, patient with no ECG changes related. To hyperkalemia is not a pressing clinical issue. I try to actually look this up one time before the conference, and I went back actually 50 years. But I couldn't find a paper that actually, you know, verify this, I would say is sort of a perception that really is not

evidence based. So, a couple of practical issues, we may not actually have ready access to the patient's Baseline electrocardiogram anyway and left. Ventricular hypertrophy and other causes of repolarization abnormality, they confuse the issue of what is actually a normal electric cardiogram for the individual patient. Also, a single electrocardiogram is a snapshot in time, and what happens hours, or even minutes might look different.

So, when we see a patient with a single ECG, and a single web value, we don't have the ability to see the trajectory of hyperkalemia prospectively. We don't know what's going to happen for hours in the Sure. So another issue unique to the Nephrology world is conventional hemodialysis patients who are hyperkalemic. Only a certain times particularly after the long enter dialectic interval on say

Monday morning. If they dialyze Monday, Wednesday or Friday, or Tuesday morning, if they dialyze Tuesday, Thursday or Saturday, it's really a type of cyclic hyperkalemia with a rapid drop occurring. During the Asus run and the large Delta K which occurs during the dialysis run is also likely an incubator for certain type of arrhythmias, particularly paroxysmal atrial

fibrillation. So when the patient develops hyperkalemia, they may be at risk for other types of revenues to not just ventricular fibrillation but there's also the issue of their have a high potassium and then they suddenly have a low potassium. This topic by the way is now the subject of a Tseebo controlled randomized, double-blind prospective trial, in hemodialysis patients with chronic hyperkalemia. The trial is called dialyze outcomes. It is just started.

And I would again, if anyone's interested in, go to trials.gov to check it out. But it's testing the efficacy of a potassium binder versus placebo. For reducing cardiovascular events, and hyperkalemic, hemodialysis patients. Check as it is, a Cardiology you probably. We do a lot of Echoes In the evaluation of transplant candidates. Do you see particular challenges in that group of patients, great question, Roberto? Because this is something that I like to rail about. With my colleagues.

They don't like to hear it because, you know, it's like certain things. It's just go away. My biggest personal headache with outpatient hyperkalemia because of my unusual practice is in the setting of cardiac stress testing in kidney transplant candidates who in the u.s. either are on dialysis or have a need. You're far less than 20 to be transplant eligible.

Some of our patients can may come from as far as 300 kilometers away and we may not have recent lab testing for either electrolytes, including potassium, or even a baseline electrocardiogram. And I might add that when it actually comes to the practice of doing stress testing in the u.s. at least there are no societal guidelines related to what a potassium value should be for a stress test nor are there ones for hemoglobin or serum glucose.

It's more do - don't tell. So a not infrequent occurrence for me is when an outpatient shows up with ECG changes that are sort of nondescript. Can't really tell what they if they might be newer old. And we don't have a recent potassium. So as you can imagine, trying to figure out, if somebody has a potassium value in the mid 6 range, and this has happened to be on multiple occasions.

It is not good for our workflow to have to deal with a patient with severe hypokalemia and then try to Manage them in the Echo lab because that's not what they're there for. I did actually present one of these cases that ASN kidney week in 2019. So the topic is not totally

unknown. But I would say it's something that it's like, it's just another thing that people don't want to hear about, because it just like it complicates life and people don't want their lives to be complicated any more than it has to be. So don't ask don't tell is sort of been the informal recommendations for this particular issue but as you can imagine Roberto I I'm never comfortable with not asking questions and not answering questions. Now, do you have an opinion

about the use of Ro potassium? Binders in hospitalized patients and also in those in transition to outpatient care, that's a real interesting and somewhat. Controversial question. If you look at the que digo diagram in the, in the manuscript about the treatment of acute hyperkalemia, there is a suggestion of consider all potassium binders, and I think Mitch therapy in hospitalized patients, but we definitely have used it at our own institution, even example, where it might

help. And then episode occurs at three in the morning and you're using doing everything else that works. Including redistribute of therapies, you still may have a problem where the trajectory of hyperkalemia puts you into very dangerous territory and you would like something to slow it down just a little bit if possible. So you see what, why not? Just put the patient on a cute. Dialysis, the answer is well three of them. Morning, sometimes that's not a

five-minute procedure. And a lot of institutions in Minnesota, we have big snowstorm. So sometimes the ability even to do a cute, dialysis might be affected by, you know, the weather, and things like that, in terms of availability of emergency technical staff. So the the oral potassium binder might buy you a little time, it's not going to prevent dialysis, it's not going to make the person necessarily normal Kaylee make, but it might buy a little extra time before you get into the lethal.

In your range. There isn't much downside. So I think it's sort of a niche therapy by the clinicians and it's usually something you would do really in an acute setting.

And it's not instead of dialysis, dialysis is still the main therapy for removing potassium from the body and it's going to be the Mainstay of therapy for a Nephrology practice, but it might help be a little bit of a buffer to give the patient a little more time to get to the point where they can safely and initiating a cute. Dialysis. And then sometimes the patient to develops acute hyperkalemia might transition to Chronic therapy when they leave the hospital.

So if the thought is that they're likely to be at risk for the episode again, that it makes sense to continue the therapy, but I think the bottom line is these decisions have to be individualized at a particular edit. The edit individual patient level. I would say, it's not routine, practice to be giving patients in hospital for to oral potassium, binders.

It's kind of a niche therapy. Well, that's all we have for A thank you for listening and I hope you enjoyed program and thank you Chuck for joining me and sharing all those very valuable insights. It was a true pleasure speaking with you today. Thanks Roberto. It's been a pleasure being on this podcast with you and always good to be working with JD go. I'm dr. Roberto Cavalli, and to access this and other episodes of the series visit Katie google.org / podcast, thanks for listening.

This episode was provided by by KD go and supported by V4 Pharma.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android